{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:34:50Z","timestamp":1777577690434,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","award":["2008\u2010005767\u201034"],"award-info":[{"award-number":["2008\u2010005767\u201034"]}],"id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>To investigate, in a 26\u2010week, open\u2010label, randomized, treat\u2010to\u2010target trial, the efficacy and safety of insulin degludec\/insulin aspart (<jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp) once daily vs insulin glargine (<jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar) once daily in adults with Type 2 diabetes, inadequately controlled on basal insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Participants were randomized (1:1) to <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily or <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar once daily in combination with existing oral antidiabetic drugs. <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily was administered with the main evening meal or the largest meal of the day (agreed at baseline); dosing time was maintained throughout the trial. Participants titrated their insulin dose weekly to a mean pre\u2010breakfast self\u2010measured plasma glucose target [3.9\u20134.9 mmol\/l (70\u201389 mg\/dl)].<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily was non\u2010inferior to <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar once daily in reducing HbA<jats:sub>1c<\/jats:sub> after 26 weeks [mean estimated treatment difference <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily \u2212 <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar once daily: \u22120.03% (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> \u22120.20, 0.14)]. The evening meal glucose increment was significantly lower with <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily vs <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar once daily [estimated treatment difference <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily \u2212 <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar once daily: \u22121.32 mmol\/l (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> \u22121.93, \u22120.72); <jats:italic>P<\/jats:italic> &lt; 0.05]. The overall confirmed hypoglycaemia rate was higher with <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily (estimated rate ratio 1.43; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 1.07, 1.92; <jats:italic>P<\/jats:italic> &lt; 0.05). The rate of nocturnal hypoglycaemia did not significantly differ between the <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp and <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar groups [estimated rate ratio 0.80 (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content> 0.49, 1.30); not significant].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In participants with Type 2 diabetes inadequately controlled on basal insulin, <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp once daily improved glycaemic control and was non\u2010inferior to <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar once daily. <jats:styled-content style=\"fixed-case\">ID<\/jats:styled-content>egAsp led to higher rates of overall hypoglycaemia than <jats:styled-content style=\"fixed-case\">IG<\/jats:styled-content>lar, with no significant difference in rates of nocturnal hypoglycaemia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.13125","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:31:02Z","timestamp":1459384262000},"page":"180-188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Efficacy and safety of once\u2010daily insulin degludec\/insulin aspart compared with once\u2010daily insulin glargine in participants with Type 2 diabetes: a randomized, treat\u2010to\u2010target study"],"prefix":"10.1111","volume":"34","author":[{"given":"S.","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Diabetes Diabetes Care Centre Thiruvananthapuram India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. C.","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University Bundang Hospital Gyeonggi\u2010do South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. G.","family":"Demira\u011f","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Baskent University Hospital, Altunizade Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. V.","family":"Skj\u00f8th","sequence":"additional","affiliation":[{"name":"Department of Medical and Science, Liraglutide and Obesity Novo Nordisk A\/S S\u00f8borg Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Endahl","sequence":"additional","affiliation":[{"name":"Department of R&amp;D Insight Novo Nordisk A\/S Bagsvaerd Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Bode","sequence":"additional","affiliation":[{"name":"Atlanta Diabetes Associates Atlanta GA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0413"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(95)01064-K"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905479"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-1348"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0117.x"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP10079.OR"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903354674"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01395.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0732"},{"key":"e_1_2_9_12_1","unstructured":"HavelundS.Insulin degludec (IDeg) and insulin aspart (IAsp) can be coformulated such that the formation of IDeg multi\u2010hexamers and IAsp monomers is retained upon subcutaneous injection. Presented at the American Diabetes Association 21\u201325 June 2013 Chicago USA (Poster 945\u2010P)."},{"key":"e_1_2_9_13_1","first-page":"255","article-title":"Distinct prandial and basal glucose\u2010lowering effects of insulin degludec\/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus","volume":"5","author":"Heise T","year":"2014","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00654.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2009.01144.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2908"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2014.09.026"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12097"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13125","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T07:38:18Z","timestamp":1695973098000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/dme.13125"],"URL":"https:\/\/doi.org\/10.1111\/dme.13125","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"assertion":[{"value":"2016-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}